© Synapse Social LLC, 2026
October 4, 2011 Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial Daniel D. Von Hoff Translational Genomics Research Institute RR Ramesh K. Ramanathan Ironwood Pharmaceuticals (United States) MB Mitesh J. Borad Jacksonville College Ver todo Puntos clave Los puntos clave no están disponibles para este artículo en este momento.
Resumen The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.
Leer artículo completo
Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial | Synapse
Hoff et al. (Tue,) studied this question.
Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial 2007 · 31 citations